Inhaled preparation for COPD

PreclinicalSmall molecule

GGuangzhou Institute of Respiratory Disease

Inhaled preparation for COPD is one of 40 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

120 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

EXDENSUR

GGlaxo Dba Glaxosmithkline

Phase 3

2 2

Lunsekimig

Sanofi

Phase 3

3 3

Tozorakimab

AstraZeneca

Phase 3

2 4

CM310

KKeymed Biosciences Co.Ltd

Phase 3

1 5

Astegolimab

Roche

Phase 3

3 6

CM512

KKeymed Biosciences Co.Ltd

Phase 2

1 7

Titrated Oxygen

RRigshospitalet, Denmark

Phase 3

1 8

HSK39004

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

2 9

RLS-0071

RReAlta Life Sciences, Inc.

Phase 2

1 10

Calciferol

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)

Recruiting·GGuangzhou Institute of Respiratory Disease··NCT06772454·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inhaled preparation for COPD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled preparation for COPD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled preparation for COPD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Institute of Respiratory Disease company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuangzhou Institute of Respiratory Disease

Inhaled preparation for COPD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

References

Drug Info

Quick Facts

Related News